Butorphanol (Stadol): A study in problems of current drug information and control

Neurology

Volumn 48, Issue 5, 1997, Pages 1156-1160

  Fisher, Morris A ^a   Glass, Stephanie ^b  

^a HINES VA HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUTORPHANOL; BUTORPHANOL TARTRATE; NOSE SPRAY; OPIATE DERIVATIVE;

DRUG DEPENDENCE; DRUG INDICATION; DRUG INFORMATION; FOOD AND DRUG ADMINISTRATION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MIGRAINE; PRIORITY JOURNAL; REVIEW;

EID: 0030960838     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.5.1156     Document Type: Review

References (29)

1. Reisine T, Pasternak G. Opioid analgesics and antagonists. In: Goodman LS, Gilman A, eds. The pharmacological basis of therapeutics. New York: McGraw-Hill, 1996;521-555.
2. Drug Advisory Committee, FDA, June 1, 1978.
3. Transcript of Proceedings, New Mexico Board of Pharmacy, August 22, 1994.
4. Drug Abuse Advisory Committee, FDA, June 1, 1978.
5. Caplan LR, Thomas C, Banks G. Central nervous system complications of addiction to "T's and Blues." Neurology 1982;32: 623-628.
6. Drug Abuse Advisory Committee, FDA, June 1, 1978.
7. New Drug Application 17-857. FDA, 1978.
8. Vandam LR. Butorphanol. N Engl J Med 1980;302:381-384.
9. Evans WS, Bowen JN, Giordano FL, Clark B. A case of Stadol dependence. JAMA 1985;253:2191-2192.
10. Brown GR. Stadol dependence: another case. JAMA 1985;254: 910.
11. Austin RP. Diversion of butorphanol. Am J Hosp Pharm 1983; 40:1306.
12. Smith SG, Davis WM. Non-medical use of butorphanol and diphenhydramine. JAMA 1984;252:1010.
13. Drug Abuse Advisory Committee, FDA, February 4, 1991.
14. NDA 19890. FDA, 1991.
15. Drug Abuse Advisory Committee, FDA, February 4, 1991.
16. Robbins L. Stadol nasal spray: treatment for migraine? [letter]. Headache 1993;33:220.
17. Texas State Board of Pharmacy Newsletter. Fall/Winter 1993-94, p 3.
18. Letter from Mr. Fred S. Brinkley, Jr., Executive Director/ Secretary Texas Board of Pharmacy to Dr. David R. Smith, Commissioner of Health, April 8, 1992.
19. FDA memorandum from Heinz G. Wilms, Director of Federal State Relations, June 24, 1994.
20. FDA memorandum from Richard H. Barnes, Director Federal-State Relations, November 28, 1995.
21. Iranon G. Testimony on Senate Bill 1593 - a Bill for an act relating to controlled substances. State of Hawaii. March 23, 1995.
22. Transcript of Proceedings, New Mexico Board of Pharmacy, August 22, 1994.
23. Drug Abuse Advisory Committee, FDA, June 1, 1978.
24. Butorphanol nasal spray for pain. Med Lett 1993;35:105-106.
25. Rapoport AM. Severe headache: focus on migraine. Neurology 1994;44(suppl 3):6-28.
26. Hoffert MJ, Couch JR, Diamond S. et al. Transnasal butorphanol in the treatment of acute migraine. Headache 1995;35: 65-69.
27. Saper JR. Transnasal butorphanol for acute migraine. Topics in Pain Management 1995;10:45-47.
28. Abraham J. Science, politics, and the pharmaceutical industry: controversy and bias in drug regulation. New York: St. Martin's Press, 1995.
29. Wilkes MS, Doblin BH, Shapiro MF. Pharmaceutical advertisements in leading medical journals: experts' assessments. Ann Intern Med 1992;116:912-919.